AVIR - Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus | Benzinga
Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced Wednesday new data from the lead-in cohort (n=60) of the company’s ongoing Phase 2 combination study of bemnifosbuvir for hepatitis C virus (HCV).
With an eight-week treatment duration in 60 patients, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), the study’s primary efficacy endpoint.
The company will also present preclinical data further demonstrating a high barrier to resistance and pharmacokinetics for bemnifosbuvir and a low risk of drug-drug interactions ...